

**Independent Auditor's Review Report on review of Interim standalone financial results**

**To the Board of Directors of Archean Chemical Industries Limited**

We have reviewed the accompanying Statement of Unaudited standalone financial results ("the Statement") of Archean Chemical Industries Limited ("the Company") for the quarter and half year ended 30<sup>th</sup> September 2023. The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended which has been initialed by us for identification purposes.

**Management's Responsibility**

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

**Auditor's Responsibility**

Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

**Conclusion**

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For PKF Sridhar & Santhanam LLP**

Chartered Accountants

Firm's Registration No. 003990S/S200018

*S. Prasana Kumar*

**S.Prasana Kumar**

Partner

Membership No. 212354

Place: Chennai

Date: 31<sup>st</sup> October 2023

UDIN No: 23212354BGYDWQ1620



Archcan Chemical Industries Limited  
CIN: L24298TN2009PLC072270  
Regd Office: No.2, North Crescent Road, T Nagar, Chennai - 600 017  
Statement of Unaudited Standalone Financial Results for the Quarter and Half year ended 30th September, 2023

(Amount Rs. in Lakhs)

S.No	Particulars	Quarter ended September 30, 2023	Quarter ended June 30, 2023	Quarter ended September 30, 2022	Half Year ended September 30, 2023	Half Year ended September 30, 2022	Year ended March 31, 2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
(I)	Revenue from operations	29,046.88	34,309.39	29,349.46	63,356.27	69,376.83	1,44,106.59
(II)	Other income	1,157.50	1,120.38	1,915.27	2,277.88	2,793.56	4,417.89
(III)	<b>Total Income (I+II)</b>	<b>30,204.38</b>	<b>35,429.77</b>	<b>31,264.73</b>	<b>65,634.15</b>	<b>72,170.39</b>	<b>1,48,524.48</b>
(IV)	<b>Expenses</b>						
	Cost of materials consumed	1,194.35	1,352.02	847.26	2,546.37	2,331.82	4,570.40
	Purchase of stock in trade	-	-	-	-	442.82	442.82
	Changes in inventories of finished goods and work-in-progress	682.39	1,634.19	2,084.35	2,316.58	648.99	(4,740.18)
	Employee benefits expense	1,919.63	2,033.64	1,146.93	3,953.27	2,123.83	7,202.44
	Finance costs	200.03	305.55	3,497.25	505.58	7,412.26	9,695.89
	Depreciation and amortisation expenses	1,745.56	1,746.64	1,685.51	3,492.20	3,447.57	6,850.89
	Other expenses	15,691.24	15,815.28	13,400.47	31,506.52	35,839.27	73,194.35
	<b>Total Expenses</b>	<b>21,433.20</b>	<b>22,887.32</b>	<b>22,661.77</b>	<b>44,320.52</b>	<b>52,246.56</b>	<b>97,216.61</b>
(V)	<b>Profit before exceptional items and tax (III - IV)</b>	<b>8,771.18</b>	<b>12,542.45</b>	<b>8,602.96</b>	<b>21,313.63</b>	<b>19,923.83</b>	<b>51,307.87</b>
(VI)	Exceptional item	-	-	-	-	-	-
(VII)	<b>Profit before tax (V + VI)</b>	<b>8,771.18</b>	<b>12,542.45</b>	<b>8,602.96</b>	<b>21,313.63</b>	<b>19,923.83</b>	<b>51,307.87</b>
(VIII)	<b>Tax expense</b>						
	(i) Current tax	1,928.29	2,841.49	-	4,769.78	-	2,362.62
	(ii) Deferred tax	208.20	283.87	2,211.92	492.07	5,068.99	10,579.87
	<b>Total tax expenses</b>	<b>2,136.49</b>	<b>3,125.36</b>	<b>2,211.92</b>	<b>5,261.85</b>	<b>5,068.99</b>	<b>12,942.49</b>
(IX)	<b>Profit after tax (VII - VIII)</b>	<b>6,634.69</b>	<b>9,417.09</b>	<b>6,391.04</b>	<b>16,051.78</b>	<b>14,854.84</b>	<b>38,365.38</b>
(X)	<b>Other comprehensive income</b>						
	(i) Items that will not be reclassified to profit or loss						
	- Remeasurement of defined benefit obligations	(25.81)	(9.44)	(2.78)	(35.25)	(7.65)	38.11
	(ii) Income tax relating to above	6.49	2.38	0.70	8.87	1.93	(9.59)
	<b>Total other comprehensive income (+/-ii)</b>	<b>(19.32)</b>	<b>(7.06)</b>	<b>(2.08)</b>	<b>(26.38)</b>	<b>(5.72)</b>	<b>28.52</b>
(XI)	<b>Total comprehensive Income (IX + X)</b>	<b>6,615.37</b>	<b>9,410.03</b>	<b>6,388.96</b>	<b>16,025.40</b>	<b>14,849.12</b>	<b>38,393.90</b>
(XII)	Paid-up equity share capital (Face value of Rs. 2 each)	2,461.06	2,461.06	1,926.67	2,461.06	1,926.67	2,461.06
(XIII)	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						1,40,790.85
(XIV)	Earnings per share of Rs 2 each (Not Annualised)						
	- Basic	5.39	7.65	6.19	13.04	14.38	34.76
	- Diluted	5.37	7.62	6.19	12.99	14.38	34.69

## b. Statement of assets and liabilities

(Amount Rs. in Lakhs)

S.No	Particulars	As at	As at
		September 30, 2023	March 31, 2023
		Unaudited	Audited
<b>I</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-Current Assets</b>		
	(a) Property, plant and equipment	1,05,224.68	1,06,480.86
	(b) Capital work in progress	4,804.45	3,319.70
	(c) Right-of-use assets	2,919.28	3,249.59
	(d) Intangible assets	14.45	17.30
	(e) Financial assets:		
	(i) Investments	500.00	500.00
	(ii) Loans	3,163.53	1,405.06
	(iii) Other financial assets	561.38	2,301.61
	(f) Other non current assets	1,190.25	681.71
	<b>Total Non-current assets</b>	<b>1,18,378.02</b>	<b>1,17,955.83</b>
<b>2</b>	<b>Current assets</b>		
	(a) Inventories	14,273.23	16,776.37
	(b) Financial assets:		
	(i) Current investments	32,858.12	21,007.73
	(ii) Trade receivables	11,886.59	11,774.34
	(iii) Cash and cash equivalents	3,087.04	527.20
	(iv) Bank balances other than (iii) above	2,665.00	2,669.99
	(v) Loans	55.18	42.82
	(vi) Other financial assets	1,730.55	1,646.76
	(c) Other current assets	3,365.22	3,184.09
	<b>Total current assets</b>	<b>69,920.93</b>	<b>57,629.30</b>
	<b>TOTAL ASSETS</b>	<b>1,88,298.95</b>	<b>1,75,585.13</b>
<b>II</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity</b>		
	(a) Equity share capital	2,461.06	2,461.06
	(b) Other equity	1,54,529.51	1,40,790.85
	<b>Total equity</b>	<b>1,56,990.57</b>	<b>1,43,251.91</b>
<b>2</b>	<b>Liabilities</b>		
	<b>Non-Current liabilities</b>		
	(a) Financial liabilities:		
	(i) Borrowings	69.74	78.80
	(ii) Lease liabilities	3,231.12	3,571.20
	(b) Provisions	4.21	4.79
	(c) Deferred tax liabilities (Net)	12,028.65	11,545.46
	<b>Total non-current liabilities</b>	<b>15,333.72</b>	<b>15,200.25</b>
	<b>Current Liabilities</b>		
	(a) Financial liabilities:		
	(i) Borrowings	2,517.72	2,070.41
	(ii) Lease liabilities	624.96	1,218.12
	(iii) Trade payables		
	(A) total outstanding dues of micro and small enterprises	781.34	1,796.83
	(B) total outstanding dues of creditors other than above	9,260.36	7,757.19
	(iv) Other financial liabilities	1,787.09	2,045.65
	(b) Other current liabilities	223.02	1,935.70
	(c) Current Tax Liabilities	722.89	283.37
	(d) Provisions	57.28	25.70
	<b>Total current liabilities</b>	<b>15,974.66</b>	<b>17,132.97</b>
	<b>Total Liabilities</b>	<b>31,308.38</b>	<b>32,333.22</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>1,88,298.95</b>	<b>1,75,585.13</b>

**Archean Chemical Industries Limited**  
CIN: L24298TN2009PLC072270  
Regd Office: No.2, North Crescent Road, T Nagar, Chennai - 600 017

**Notes to the financial results:**

- 1) Archean Chemical Industries Limited was incorporated on July 14, 2009. The Company is into manufacturing of Marine Chemicals. The manufacturing location is in Gujarat.
- 2) The above financial results have been prepared in accordance with the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended and in conformity with Ind AS, as prescribed under Sec 133 of Companies Act, 2013 read with relevant rules issued thereunder and accounting principles generally accepted in India. These financial results have been reviewed by the Audit Committee, approved by the Board of Directors at their meeting held on October 31, 2023.
- 3) The Company is primarily engaged in the business of manufacture of marine chemicals which is considered as one reportable segment and hence, no additional disclosures with respect to segment information have been made under Ind AS 108 - Operating Segments.
- 4) The Company has completed the Initial Public Offer (IPO) of 3,59,28,869 Equity shares of face value of Rs. 2 each at an issue price of Rs. 407 per equity share comprising offer for sale of 1,61,50,000 equity shares by selling shareholders and fresh issue of 1,97,78,869 shares. The equity shares of the Company were listed on National Stock Exchange of India Limited ("NSE") and BSE limited ("BSE") on November 21, 2022. The Net Proceeds from IPO of Rs. 768.32 crores has been utilised towards repayment of Non Convertible Debentures amounting to Rs.644 Crores and the balance was utilised towards general corporate purpose.
- 5) Pursuant to the resolution passed by the Board and resolution passed at the Nomination Remuneration Committee on October 07,2022 the Company has granted the issuance of 4,91,400 Employee Stock Options (ESOP's) to the eligible employees of the Company in accordance with Archean Chemical -Employee Stock Option Plan 2022. The Vesting Period of ESOP is between 12 months to 60 months.
- 6) The Company entered into Memorandum of Undertaking (MOU) dated August 10,2010, with Government of Gujarat (GOG) for the Land lease which expired on July 31, 2018 and the Company had made an application for renewal on December 28, 2017. As per the MOU with GOG, the lease term can be further extended for a duration and conditions as mutually agreed at that time. There is also a GOG circular no 1597/1372/8 dated October 9, 2017 which states that such leases can be extended for a period of thirty years. The Company has also been receiving demand note annually for the revised lease rents as per GoG circular and the company has been making these payments. Management made an assessment of the facts disclosed above and taking into consideration of similar experiences during renewal in group company, is confident of obtaining the renewal of land lease after expiry. The Useful life of PPE and ROU assets have been determined by the management considering that the lease would be extended. The entire production facility is located on this leased land.
- 7) The Company has incorporated Idealis Chemicals Private Limited on 5th October, 2023 and Neun Infra Private Limited on 3rd October, 2023, both being Wholly Owned Subsidiary of Archean Chemical Industries Limited. The Companies have not commenced its commercial operations.
- 8) The Board of Directors have declared an interim dividend of Re. 1/- per equity Share of Rs. 2/- each for the financial year ending March 31, 2024 amounting to Rs. 12.32 Crores. The record date for payment of interim dividend is fixed as November 17, 2023.
- 9) The implementation of the Code on Social Security, 2020 is getting postponed. The Company will assess the impact thereof and give effect in the Financial Statements when the date of implementation of the codes and the Rules / Schemes thereunder are notified.
- 10) Previous year / period figures have been regrouped wherever necessary.

**For and on behalf of the Board of Directors**

**PENDURT** Digitally signed by  
**HI RANJIT** PENDURTHI RANJIT  
Date: 2023.10.31  
12:59:26 +05'30'

**P. Ranjit**  
**Managing Director**  
**DIN : 01952929**

Place : Chennai  
Date : October 31, 2023

Archean Chemical Industries Limited				
Statement of unaudited Standalone Cash flows for the Half Year ended September 30, 2023				
(Amount Rs. in Lakhs)				
Particulars	For the Half year ended September 30, 2023		For the Half year ended September 30, 2022	
<b>A. Cash flows from operating activities</b>				
Profit before income tax		21,313.63		19,923.83
<b>Adjustments for :</b>				
Depreciation and amortisation expenses	3,492.20		3,447.57	
Finance costs recognised in profit or loss	505.58		7,412.26	
Profit on sale of mutual funds	(971.69)		(138.73)	
Interest income from fixed deposit	(183.46)		(183.18)	
(Profit)/Loss on sale of asset	3.58		(0.25)	
Issue of Employee stock options	792.41		-	
Provision for doubtful receivables / advances	(164.92)		817.15	
Write back of payables	(595.28)		-	
Unrealised net foreign exchange (gain) / loss	(501.10)		679.94	
<b>Operating profit before working capital changes</b>		<b>2,377.32</b>		<b>12,034.76</b>
<b>Movements in working capital :</b>				
(Increase) / decrease in trade receivables	523.73		6,162.22	
(Increase) / decrease in inventories	2,503.14		647.47	
(Increase) / decrease in other assets	1,186.74		(463.82)	
Increase / (decrease) in trade payables	477.86		(2,250.74)	
Increase / (decrease) in provisions	31.00		(39.72)	
Increase / (decrease) in other liabilities	(2,006.49)		(6,887.01)	
		<b>2,715.98</b>		<b>(2,831.60)</b>
Cash generated from operations		26,406.93		29,126.99
Income Tax paid		(4,330.26)		(800.00)
<b>Net cash generated from operating activities</b>		<b>22,076.67</b>		<b>28,326.99</b>
<b>B. Cash flows from investing activities</b>				
Interest received	183.46		183.18	
Investment in Mutual funds	(10,878.70)		(1,193.65)	
Loan to subsidiary	(1,758.47)		-	
Investment in / maturity of bank deposits, net	(230.17)		(559.26)	
Acquisition of property, plant and equipment	(3,480.69)		(4,525.79)	
Proceeds from sale of property, plant and equipment	89.50		1.77	
<b>Net cash used in investing activities</b>		<b>(16,075.07)</b>		<b>(6,093.75)</b>
<b>C. Cash flows from financing activities</b>				
Proceeds from borrowings	2,500.00		12,157.04	
Repayment of NCD	-		(14,080.00)	
Payment of Dividend for FY 22-23	(3,076.32)		-	
Repayment of Other borrowings	(2,061.75)		(295.14)	
Repayment towards lease liabilities	(650.02)		(714.05)	
Interest paid - Others	(153.67)		(14,356.03)	
<b>Net cash used in financing activities</b>		<b>(3,441.76)</b>		<b>(17,288.18)</b>
<b>Net increase/ (decrease) in cash and cash equivalents</b>		<b>2,559.84</b>		<b>4,945.06</b>
Cash and cash equivalents as at the beginning of the Period/Year		527.20		724.68
<b>Cash and Cash equivalents as at the end of the Period/Year</b>		<b>3,087.04</b>		<b>5,669.74</b>

For and on behalf of the Board of Directors

PENDURT  
HI RANJIT

Digitally signed by  
PENDURTHI RANJIT  
Date: 2023.10.31  
12:59:45 +05'30'

**P. Ranjit**  
**Managing Director**  
**DIN : 01952929**

Place : Chennai  
Date : October 31, 2023

**Independent Auditor's Review Report on Review of interim consolidated financial results****To the Board of Directors of Archean Chemical Industries Limited**

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial results of Archean Chemical Industries Limited (the "parent") and its subsidiary (the parent and subsidiary together referred to as the "Group"), for the quarter and half year ended 30<sup>th</sup> September 2023 (the "Statement") being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended which has been initialed by us for identification purpose.

**2. Management's Responsibility**

The Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("IndAS-34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, and other accounting principles generally accepted in India.

**3. Auditor's Responsibility**

Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently doesn't enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entity: Acume Chemicals Private Limited (Subsidiary Company)

**5. Conclusion**

Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditors referred in paragraph 6 below, nothing has come to our attention that causes us to believe that the Statement prepared, in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



## Other Matters

6. We did not review the interim financial information of the subsidiary included in the consolidated unaudited financial results, whose financial results reflect total assets of Rs.3,703.06 lakhs as at 30<sup>th</sup> September 2023, total revenue of Rs. Nil and Nil, total loss after tax (net) of (Rs.34.63 lakhs) and (Rs.66.10 lakhs), total comprehensive income of (Rs.34.63 lakhs) and (Rs.66.10 lakhs) for the quarter and half year ended 30<sup>th</sup> September 2023. These interim financial information / results and other financial information have been reviewed by another auditor, whose report has been furnished to us and our conclusion, in so far as it relates to the amounts and disclosures included in respect of the subsidiary, is based solely on the report of the other auditor and procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of this matter.

For **PKF Sridhar & Santhanam LLP**

Chartered Accountants

Firm's Registration No. 003990S/S200018

*S. Prasana Kumar*

**S. Prasana Kumar**

Partner

Membership No. 212354

Place: Chennai

Date: 31<sup>st</sup> October 2023

UDIN: 23212354BGYDWR5652



Archean Chemical Industries Limited  
CIN: L24298TN2009PLC072270  
Regd Office: No.2, North Crescent Road, T Nagar, Chennai - 600 017  
Statement of Unaudited Consolidated Financial Results for the Quarter and Half Year ended 30th September, 2023

(Amount Rs. in Lakhs)

S.No	Particulars	Quarter ended September 30, 2023	Quarter ended June 30, 2023	Quarter ended September 30, 2022	Half Year ended September 30, 2023	Half Year ended September 30, 2022	Year ended March 31, 2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
(I)	Revenue from operations	29,046.45	34,309.38	29,349.46	63,355.83	69,376.83	1,44,106.59
(II)	Other income	1,119.20	1,092.95	1,891.80	2,212.15	2,746.62	4,327.13
(III)	<b>Total Income (I+II)</b>	<b>30,165.65</b>	<b>35,402.33</b>	<b>31,241.26</b>	<b>65,567.98</b>	<b>72,123.45</b>	<b>1,48,433.72</b>
(IV)	<b>Expenses</b>						
	Cost of materials consumed	1,194.35	1,352.02	847.26	2,546.37	2,331.82	4,570.40
	Purchase of stock in trade	-	-	-	-	442.82	442.82
	Changes in inventories of finished goods and work-in-progress	682.39	1,634.19	2,084.35	2,316.58	648.99	(4,740.18)
	Employee benefits expense	1,920.04	2,033.75	1,146.93	3,953.79	2,123.83	7,204.70
	Finance costs	185.27	301.25	3,497.26	486.52	7,412.27	9,695.90
	Depreciation and amortisation expenses	1,750.30	1,750.77	1,689.50	3,501.07	3,451.92	6,863.34
	Other expenses	15,703.92	15,825.89	13,411.71	31,529.81	35,863.92	73,229.14
	<b>Total Expenses</b>	<b>21,436.27</b>	<b>22,897.87</b>	<b>22,677.01</b>	<b>44,334.14</b>	<b>52,275.57</b>	<b>97,266.12</b>
(V)	<b>Profit before exceptional items and tax (III - IV)</b>	<b>8,729.38</b>	<b>12,504.46</b>	<b>8,564.25</b>	<b>21,233.84</b>	<b>19,847.88</b>	<b>51,167.60</b>
(VI)	Exceptional item	-	-	-	-	-	-
(VII)	<b>Profit before tax (V + VI)</b>	<b>8,729.38</b>	<b>12,504.46</b>	<b>8,564.25</b>	<b>21,233.84</b>	<b>19,847.88</b>	<b>51,167.60</b>
(VIII)	<b>Tax expense</b>						
	(i) Current tax	1,928.29	2,841.49	-	4,769.78	-	2,362.62
	(ii) Deferred tax	201.03	277.35	2,205.22	478.38	5,048.98	10,549.06
	<b>Total tax expenses</b>	<b>2,129.32</b>	<b>3,118.84</b>	<b>2,205.22</b>	<b>5,248.16</b>	<b>5,048.98</b>	<b>12,911.68</b>
(IX)	<b>Profit after tax (VII - VIII)</b>	<b>6,600.06</b>	<b>9,385.62</b>	<b>6,359.03</b>	<b>15,985.68</b>	<b>14,798.90</b>	<b>38,255.92</b>
(X)	<b>Other comprehensive income</b>						
	(i) Items that will not be reclassified to profit or loss						
	- Remeasurement of defined benefit obligations	(25.81)	(9.44)	(2.78)	(35.25)	(7.65)	38.11
	(ii) Income tax relating to above	6.49	2.38	0.70	8.87	1.93	(9.59)
	<b>Total other comprehensive income (i+ii)</b>	<b>(19.32)</b>	<b>(7.06)</b>	<b>(2.08)</b>	<b>(26.38)</b>	<b>(5.72)</b>	<b>28.52</b>
(XI)	<b>Total comprehensive income for the period/year (IX + X)</b>	<b>6,580.74</b>	<b>9,378.56</b>	<b>6,356.95</b>	<b>15,959.30</b>	<b>14,793.18</b>	<b>38,284.44</b>
(XII)	Paid-up equity share capital (Face value of Rs. 2 each)	2,461.06	2,461.06	1,926.67	2,461.06	1,926.67	2,461.06
(XIII)	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						1,40,640.92
(XIV)	Earnings per share of Rs.2 each (Not Annualised)						
	- Basic	5.36	7.63	6.16	12.99	14.33	34.66
	- Diluted	5.34	7.60	6.16	12.94	14.33	34.59



**Archean Chemical Industries Limited**  
CIN: L24298TN2009PLC072270

Regd Office: No.2, North Crescent Road, T Nagar, Chennai - 600 017

Statement of Unaudited Consolidated Financial Results for the Quarter and Half Year ended 30th September, 2023

b. Statement of assets and liabilities		(Amount Rs. in Lakhs)	
S.No	Particulars	As at	As at
		September 30, 2023	March 31, 2023
		Unaudited	Audited
<b>I</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-Current Assets</b>		
	(a) Property, plant and equipment	1,05,237.94	1,06,488.65
	(b) Capital work in progress	5,832.66	3,617.91
	(c) Right-of-use assets	4,267.32	4,502.35
	(d) Intangible assets	14.45	17.30
	(e) Financial assets:		
	(i) Other financial assets	393.65	2,193.62
	(f) Deferred tax assets (Net)	44.50	30.81
	(g) Other non current assets	2,383.60	989.98
	<b>Total Non-current assets</b>	<b>1,18,174.12</b>	<b>1,17,840.62</b>
<b>2</b>	<b>Current assets</b>		
	(a) Inventories	14,273.23	16,776.37
	(b) Financial assets:		
	(i) Current investments	32,893.16	21,007.73
	(ii) Trade receivables	11,886.06	11,774.33
	(iii) Cash and cash equivalents	3,089.55	597.26
	(iv) Bank balances other than (iii) above	2,665.00	2,669.99
	(v) Loans	55.63	42.84
	(vi) Other financial assets	1,715.42	1,631.63
	(c) Other current assets	3,400.68	3,202.57
	<b>Total current assets</b>	<b>69,978.73</b>	<b>57,702.72</b>
	<b>TOTAL ASSETS</b>	<b>1,88,152.85</b>	<b>1,75,543.34</b>
<b>II</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity</b>		
	(a) Equity share capital	2,461.06	2,461.06
	(b) Other equity	1,54,313.49	1,40,640.92
	<b>Total equity</b>	<b>1,56,774.55</b>	<b>1,43,101.98</b>
<b>2</b>	<b>Liabilities</b>		
	<b>Non-Current liabilities</b>		
	(a) Financial liabilities:		
	(i) Borrowings	69.74	78.80
	(ii) Lease liabilities	3,231.12	3,571.20
	(b) Provisions	4.21	4.79
	(c) Deferred tax liabilities (Net)	12,028.65	11,545.46
	<b>Total non-current liabilities</b>	<b>15,333.72</b>	<b>15,200.25</b>
	<b>Current Liabilities</b>		
	(a) Financial liabilities:		
	(i) Borrowings	2,517.72	2,070.41
	(ii) Lease liabilities	624.96	1,218.12
	(iii) Trade payables		
	(A) total outstanding dues of micro and small enterprises	781.34	1,796.83
	(B) total outstanding dues of creditors other than above	9,261.19	7,758.67
	(iv) Other financial liabilities	1,848.32	2,144.93
	(b) Other current liabilities	231.34	1,943.08
	(c) Current tax liabilities (Net)	722.43	283.37
	(d) Provisions	57.28	25.70
	<b>Total current liabilities</b>	<b>16,044.58</b>	<b>17,241.11</b>
	<b>Total Liabilities</b>	<b>31,378.30</b>	<b>32,441.36</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>1,88,152.85</b>	<b>1,75,543.34</b>

**Archean Chemical Industries Limited**  
CIN: L24298TN2009PLC072270  
Regd Office: No.2, North Crescent Road, T Nagar, Chennai - 600 017

**Notes to the financial results:**

- 1) Archean Chemical Industries Limited was incorporated on July 14, 2009. The Company is into manufacturing of Marine Chemicals. The manufacturing location is in Gujarat. Acume chemicals private limited, wholly owned subsidiary of the company was incorporated on November 18, 2021
- 2) The above financial results of the Company and its wholly owned subsidiary (Group) have been prepared in accordance with the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended and in conformity with Ind AS, as prescribed under sec 133 of Companies act, 2013 read with relevant rules issued thereunder and accounting principles generally accepted in India. These financial results have been reviewed by the Audit Committee, approved by the Board of Directors at their meeting held on October 31, 2023.
- 3) The Group is primarily engaged in the business of manufacture of marine chemicals which is considered as one reportable segment and hence, no additional disclosures with respect to segment information have been made under Ind AS 108 - Operating Segments.
- 4) The Holding Company has completed the Initial Public Offer (IPO) of 3,59,28,869 Equity shares of face value of Rs. 2 each at an issue price of Rs. 407 per equity share comprising offer for sale of 1,61,50,000 equity shares by selling shareholders and fresh issue of 1,97,78,869 shares. The equity shares of the Company were listed on National Stock Exchange of India Limited ("NSE") and BSE limited ("BSE") on November 21,2022. The Net Proceeds from IPO of Rs. 768.32 crores has been utilised towards repayment of Non Convertible Debentures amounting to Rs.644 Crores and the balance has been utilised towards general corporate purposes.
- 5) Pursuant to the resolution passed by the Board and resolution passed at the Nomination Remuneration Committee on October 07,2022 the Holding Company has granted the issuance of 4,91,400 Employee Stock Options (ESOP's) to the eligible employees of the Company in accordance with Archean Chemical -Employee Stock Option Plan 2022. The Vesting Period of ESOP is between 12 months to 60 months.
- 6) The Holding Company entered into Memorandum of Undertaking (MOU) dated August 10,2010, with Government of Gujarat (GOG) for the Land lease which expired on July 31, 2018 and the Holding Company had made an application for renewal on December 28, 2017. As per the MOU with GOG, the lease term can be further extended for a duration and conditions as mutually agreed at that time. There is also a GOG circular no 1597/1372/3 dated October 9, 2017 which states that such leases can be extended for a period of thirty years. The Holding Company has also been receiving demand note annually for the revised lease rents as per GoG circular and the company has been making these payments. Management made an assessment of the facts disclosed above and taking into consideration of similar experiences during renewal in group company, is confident of obtaining the renewal of land lease after expiry. The Useful life of PPE and ROU assets have been determined by the management considering that the lease would be extended. The entire production facility is located on this leased land.
- 7) The Holding Company has incorporated Idealis Chemicals Private Limited on 5th October, 2023 and Neun Infra Private Limited on 3rd October, 2023, both being Wholly Owned Subsidiary of Archean Chemical Industries Limited. The Companies have not commenced its commercial operations.
- 8) The Board of Directors of Holding Company have declared an interim dividend of Re. 1/- per equity Share of Rs. 2/- each for the financial year ending March 31, 2024 amounting to Rs. 12.32 Crores. The record date for payment of interim dividend is fixed as November 17, 2023.
- 9) The implementation of the Code on Social Security, 2020 is getting postponed. The Group will assess the impact thereof and give effect in the Financial Statements when the date of implementation of the codes and the Rules / Schemes thereunder are notified.
- 10) Previous year / period figures have been regrouped wherever necessary.

**For and on behalf of the Board of Directors**

PENDURTHI RANJIT  
HI RANJIT  
Digitally signed by  
PENDURTHI RANJIT  
Date: 2023.10.31  
13:00:05 +05'30'

**P. Ranjit**  
Managing Director  
DIN : 01952929

Place : Chennai  
Date : October 31, 2023

Archean Chemical Industries Limited				
Statement of Unaudited Consolidated Cash flows for the Half year ended September 30, 2023				
(Amount Rs. in Lakhs)				
Particulars	For the Half year ended September 30, 2023		For the Half year ended September 30, 2022	
<b>A. Cash flows from operating activities</b>				
Profit before income tax		21,233.84		19,847.88
<b>Adjustments for :</b>				
Depreciation and amortisation expenses	3,501.07		3,451.92	
Finance costs recognised in profit or loss	486.52		7,412.26	
Profit on sale of mutual funds	(972.37)		(138.73)	
Gain on conversion of CCD	-		-	
Interest income from fixed deposit	(117.05)		(136.23)	
(Profit)/Loss on sale of asset	3.58		(0.25)	
Issue of Employee stock options	792.41		-	
Provision for doubtful receivables / advances	(164.92)		817.15	
Write back of payables	(595.28)		-	
Unrealised net foreign exchange (gain) / loss	(501.10)		679.94	
<b>Operating profit before working capital changes</b>		<b>2,432.86</b>		<b>12,086.06</b>
<b>Movements in working capital :</b>				
(Increase) / decrease in trade receivables	524.26		6,162.22	
(Increase) / decrease in inventories	2,503.14		647.47	
(Increase) / decrease in other assets	343.54		(433.96)	
Increase / (decrease) in trade payables	477.21		(2,250.74)	
Increase / (decrease) in provisions	31.00		(39.72)	
Increase / (decrease) in other liabilities	(2,024.54)		(6,885.46)	
		<b>1,854.61</b>		<b>(2,800.19)</b>
Cash generated from operations		25,521.31		29,133.75
Income Tax paid		(4,330.26)		(800.00)
<b>Net cash generated from operating activities</b>		<b>21,191.05</b>		<b>28,333.75</b>
<b>B. Cash flows from investing activities</b>				
Interest received	117.05		136.23	
Investment in Mutual funds	(10,913.06)		(1,193.65)	
Investment in / maturity of bank deposits, net	(230.17)		(859.26)	
Acquisition of property, plant and equipment	(4,320.32)		(4,603.49)	
Proceeds from sale of property, plant and equipment	89.50		1.77	
<b>Net cash used in investing activities</b>		<b>(15,257.00)</b>		<b>(6,518.40)</b>
<b>C. Cash flows from financing activities</b>				
Proceeds from borrowings	2,500.00		12,157.04	
Repayment of NCDs	-		(14,080.00)	
Payment of Dividend for FY 22-23	(3,076.32)		-	
Repayment of Other borrowings	(2,061.75)		(295.14)	
Repayment towards lease liabilities	(650.02)		(714.05)	
Interest paid - Others	(153.67)		(14,356.03)	
<b>Net cash used in financing activities</b>		<b>(3,441.76)</b>		<b>(17,288.18)</b>
<b>Net increase/ (decrease) in cash and cash equivalents</b>		<b>2,492.29</b>		<b>4,527.17</b>
Cash and cash equivalents as at the beginning of the Period/Year		597.26		1,219.84
<b>Cash and Cash equivalents as at the end of the Period/Year</b>		<b>3,089.55</b>		<b>5,747.01</b>

For and on behalf of the Board of Directors

PENDURT Digitally signed by  
PENDURTHI RANJIT  
Date: 2023.10.31  
13:00:21 +05'30'  
HI RANJIT

**P. Ranjit**  
**Managing Director**  
**DIN : 01952929**

Place : Chennai  
Date : October 31, 2023